Photodynamic therapy for AMD: Smaller is better!

Acta Ophthalmologica Scandinavica

Volumn 82, Issue 6, 2004, Pages 641-642

  la Cour, Morten ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE DURATION; EDITORIAL; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; PATIENT CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SCAR; SUBRETINAL NEOVASCULARIZATION; SWEDEN; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 11244279698     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2004.00393.x     Document Type: Editorial

References (12)

1. Barbazetto I, Burdan A, Bressler NM et al. (2003): Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment. TAP and VIP Report 2. Arch Ophthalmol 121: 1253-1268.
2. Blair MP, Apte RS, Miskala PH, Bressler SB, Goldberg MF, Schachat AP & Bressler NM (2004): Retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin. Retina 24: 501-506.
3. Blinder KJ, Bradley S, Bressler NM et al. (2003): Effect of lesion size, visual acuity and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration. TAP and VIP Report 1. Am J Ophthalmol 136: 407-418.
4. Bressler NM (2001): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials. TAP Report 2. Arch Ophthalmol 119: 198-207.
5. Buch H, Vinding T, la Cour M, Appleyard M, Jensen GB & Nielsen NV (2004): Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology 111: 53-61.
6. Buch H, Vinding T, la Cour M & Nielsen NV (2001): The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. The Copenhagen City Eye Study. Acta Ophthalmol Scand 79: 441-449.
7. Frennesson CI (2004): Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization. Acta Ophthalmol Scand 82: 653-657.
8. Frennesson CI & Nilsson SE (2004): Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related-macular degeneration. Acta Ophthalmol Scand 82: 647-652.
9. Jonasson F, Arnarsson A, Sasaki H, Peto T, Sasaki K & Bird AC (2003): The prevalence of age-related maculopathy in Iceland: Reykjavik Eye Study. Arch Ophthalmol 121: 379-385.
10. Rosenfeld PJ (2004): Verteporfin in minimally classic CNV due to AMD (VIM): two-year results from a phase II controlled clinical trial. [ARVO Supplement.] Invest Ophthalmol Vis Sci 45.
11. Verteporfin in Photodynamic Therapy (VIP) Study Group (2001): Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 131: 541-560.
12. Verteporfin Roundtable 2000 and 2001 Participants & Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators & Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators (2002): Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22: 6-18.